Halaven price in Italy likely to be higher than UK price rejected by NICE
This article was originally published in Scrip
As Eisai considers how to respond to negative funding recommendations in England for Halaven, its end of life breast cancer drug, the company says it is not expecting such a bumpy ride elsewhere. Eventual approval from the Scottish Medicines Consortium looks likely, while reimbursement assessment is approaching in Italy, and at a better price than that offered in the UK, Nick Burgin, the company's European director of market access, told Scrip.
You may also be interested in...
The German pricing and reimbursement system has been successful in recognizing the value and uniqueness of orphan drugs.
Canada has announced new restrictions on exports to help mitigate the impact of measures in the US to lower medicine prices there.
In the wake of the COVID-19 pandemic and the ensuing economic fallout, pharmaceutical companies could face a range of measures designed to cut government spending on medicines. From relaxing intellectual property rights to delaying reimbursement, In Vivo examines what might be in store for industry.